Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.

Endocrine journal - 1 Oct 2006

Kumagai Atsushi, Namba Hiroyuki, Takakura Shu, Inamasu Eiko, Saenko Vladimir A, Ohtsuru Akira, Yamashita Shunichi

Abstract excerpt

The MAPK signaling pathway plays a crucial role in tumorgenesis and cell proliferation in human papillary thyroid carcinoma (PTC). Ret/PTC rearrangements, RAS and BRAF mutations, the main non-overlapping genetic alterations all leading to MAPK cascade activation, are cumulatively identified in 60...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Proto-Oncogene Proteins
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins c-raf

Share to Receptors, Growth Factor

Share to Thyroid Gland

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 16896265
DOI: 10.1507/endocrj.k06-058

Genes

ARAF
MET
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16896265-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.PMID 16896265Read ↗

BRAF Mediates RET/PTC-Induced Mitogen-Activated Protein Kinase Activation in Thyroid Cells: Functional Support for Requirement of the RET/PTC-RAS-BRAF Pathway in Papillary Thyroid CarcinogenesisSemantic proximity Read ↗

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.Semantic proximity Read ↗

BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules.Semantic proximity Read ↗

Mutational analysis of the ARAF gene in human cancers.Semantic proximity Read ↗

The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.Semantic proximity Read ↗

Roles of RAS and BRAF mutations in thyroid carcinogenesis.Semantic proximity Read ↗

BRAF mutation in thyroid cancer.Semantic proximity Read ↗

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.